West Pharmaceutical Services, Inc. (WST)
NYSE: WST · Real-Time Price · USD
333.43
+0.66 (0.20%)
At close: Dec 26, 2024, 4:00 PM
334.00
+0.57 (0.17%)
Pre-market: Dec 27, 2024, 7:05 AM EST
WST Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for WST stock have an average target of 437.75, with a low estimate of 355 and a high estimate of 536. The average target predicts an increase of 31.29% from the current stock price of 333.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for WST stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $350 → $355 | Strong Buy | Maintains | $350 → $355 | +6.47% | Dec 13, 2024 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Dec 13, 2024 |
| UBS | UBS | Hold → Strong Buy Upgrades $350 → $390 | Hold → Strong Buy | Upgrades | $350 → $390 | +16.97% | Dec 12, 2024 |
| UBS | UBS | Hold Maintains $400 → $375 | Hold | Maintains | $400 → $375 | +12.47% | Feb 16, 2024 |
| Keybanc | Keybanc | Buy Maintains $440 → $470 | Buy | Maintains | $440 → $470 | +40.96% | Feb 13, 2024 |
Financial Forecast
Revenue This Year
2.91B
from 2.95B
Decreased by -1.25%
Revenue Next Year
3.09B
from 2.91B
Increased by 6.08%
EPS This Year
6.66
from 7.88
Decreased by -15.48%
EPS Next Year
7.59
from 6.66
Increased by 14.00%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.0B | 3.3B | 3.7B | ||
| Avg | 2.9B | 3.1B | 3.4B | ||
| Low | 2.8B | 3.0B | 3.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.0% | 12.2% | 18.4% | ||
| Avg | -1.2% | 6.1% | 8.9% | ||
| Low | -4.4% | 1.9% | 3.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 7.06 | 8.10 | 9.82 |
| Avg | 6.66 | 7.59 | 8.96 |
| Low | 5.94 | 7.18 | 8.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -10.5% | 21.6% | 29.3% |
| Avg | -15.5% | 14.0% | 18.0% |
| Low | -24.6% | 7.9% | 10.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.